© Getty Images for Aurora Humanita
Moderna chairman Noubar Afeyan, whose estimated net worth is $3.7 billion, is ranked 212 on the Forbes' 400 list in 2021.
Moderna chairman Noubar Afeyan, whose estimated net worth is $3.7 billion, is ranked 212 on the Forbes' 400 list in 2021.
Moderna co-founder and chairman Noubar Afeyan along with fellow co-founder and Massachusetts Institute of Technology professor Robert Langer both made the list, with estimated net worths of $3.7 billion and $3.5 billion, respectively.
Timothy Springer, a Harvard Medical School professor and early Moderna investor, also debuted on the list with a net worth of $4.4 billion, according to Forbes.
Since Moderna became the second company to win an emergency use authorization for its COVID-19 vaccine, more than 152.3 million doses have been administered, according to data from the Centers for Disease Control and Prevention.
The company has previously said it expects to make at least $19.2 billion in sales of its COVID-19 vaccine.
Moderna's successful development of the vaccine propelled it out of the world of biotech startup obscurity and landed huge gains for shareholders.
The stock has fallen off its peak in recent weeks, but it's still up more than 189 percent since Jan. 1, and over 300 percent higher compared with a year ago.
Since its initial public offering at $22 per share in 2018, the company's stock is up more than 1,200 percent. It was last seen trading at $297.50 a share.
Comment: It's a tough job putting self-interest above public health (all in the name of public health), but somebody's gotta do it.